Medical Condition

nasopharyngeal carcinoma

Total Trials

12

Recruiting Now

12

Trial Phases

Phase 3, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for nasopharyngeal carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — nasopharyngeal carcinoma Clinical Trials

How many clinical trials are currently recruiting for nasopharyngeal carcinoma?

ClinicalMetric currently tracks 12 actively recruiting clinical trials for nasopharyngeal carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 12. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for nasopharyngeal carcinoma?

nasopharyngeal carcinoma research spans Phase 1 (1 trial), Phase 2 (2 trials), Phase 3 (5 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a nasopharyngeal carcinoma clinical trial?

Eligibility criteria for nasopharyngeal carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

Sun Yat-sen University 5 trials

Jiangxi Provincial Cancer Hospital 2 trials

Air Force Military Medical University, China 1 trial

Hunan Cancer Hospital 1 trial

Wei Jiang 1 trial

Recruiting Clinical Trials

NCT06026878 Phase 3

Recruiting

GNT Induction Treatment in Locally Advanced NPC

Air Force Military Medical Uni...

View Trial →

NCT05877872 Phase 3

Recruiting

Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma

Sun Yat-sen University

View Trial →

NCT06912711 Phase 2

Recruiting

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

Sun Yat-sen University

View Trial →

NCT06321939

Recruiting

Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma

Hunan Cancer Hospital

View Trial →

NCT06277050 Phase 3

Recruiting

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Jiangxi Provincial Cancer Hosp...

View Trial →

NCT05527470 Phase 3

Recruiting

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors

Sun Yat-sen University

View Trial →

NCT06688760

Recruiting

Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Cancer Hospital of Guangxi Med...

View Trial →

NCT05342792 Phase 3

Recruiting

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Sun Yat-sen University

View Trial →

NCT06182657

Recruiting

The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC

Jiangxi Provincial Cancer Hosp...

View Trial →

NCT06323239 Phase 2

Recruiting

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Sun Yat-sen University

View Trial →

Related Conditions

de escaltion therapy (1) herpesvirus 4 human (1) high risk cancer (1) maintenance therapy (1) head and neck squamous cell carcinoma hnscc recurrent metastatic r m (1) lymphoepithelial carcinoma (1) rhabdomyosarcoma (1) neuroblastoma (1) medulloblastoma (1) wilms tumor (1) atypical teratoid rhabdoid tumors (1) diffuse intrinsic pontine gliomas (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology